Certara Inc. (NASDAQ: CERT) announced it has entered a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for consideration of up to $135 million. The transaction is expected to close during the second quarter of 2026, subject to customary closing conditions.

The divested business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025, excluding unallocated overhead expense. The unit includes approximately 220 employees.

"Certara's strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions," said Jon Resnick, Chief Executive Officer. "This transaction underlines our commitment to the acceleration of AI-integrated modeling and simulation across the drug development lifecycle."

The company stated it plans to deploy the proceeds to drive long-term value for customers, patients, and shareholders. Certara intends to update its 2026 guidance to reflect the sale upon transaction close.

Resnick added that the transaction "enhances our ability to accelerate investment in Certara's integrated MIDD platform for customers, while sharpening our focus on product innovation and operational excellence."

Perella Weinberg Partners LP served as financial advisor to Certara, with Troutman Pepper Locke LLP as legal counsel. Guggenheim Securities, LLC advised Veristat, with McDermott Will & Schulte providing legal counsel.

The information is based on a company press release statement.